Alumis to Present at the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Alumis (Nasdaq: ALMS) announced that CEO Martin Babler will speak at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET. A live webcast will be available on the company's Investors > Events page, and a replay will be archived for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – ALMS
In the Mar 2 session, ALMS gained 0.10%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Investor conferences | Neutral | -0.0% | Planned participation in two February 2026 investor conferences with webcasts. |
| Jan 09 | Equity offering close | Negative | +7.8% | Closing of upsized underwritten public offering and full exercise of underwriters’ option. |
| Jan 07 | Offering pricing | Negative | +1.4% | Pricing of upsized underwritten public offering of common stock under existing shelf. |
| Jan 06 | Proposed offering | Negative | +10.4% | Announcement of proposed underwritten public offering of common stock. |
| Jan 06 | Phase 3 results | Positive | +95.3% | Positive topline Phase 3 envudeucitinib data in plaque psoriasis with strong efficacy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows strong positive reactions to positive clinical data and unusually positive reactions to potentially dilutive equity offerings, while routine conference participation has had minimal impact.
Over the past months, Alumis has combined major clinical and financing milestones. On Jan 6, 2026, positive Phase 3 data for envudeucitinib drove a 95.31% move, followed by a series of upsized equity offerings on Jan 6–9, 2026 that still saw positive price reactions of 1.45%, 7.82%, and 10.41%. A February 2026 investor-conference announcement on Feb 5, 2026 produced a flat -0.04% move. Today’s Leerink conference appearance fits this pattern of routine investor-relations updates with limited standalone impact.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET.
A live webcast will be available on the Alumis website in the “Investors” section under the “Events” page. A replay of the conference webcast will be archived on the company's website for 90 days.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
